Furthermore, T-cell and B-cell pathways targeted by approved RA drugs clearly emerge from the model as reflected by the impact of modulating CD86, part of the abatacept (CTLA4-Ig) target, and GON4L, expressed in B cells that are the target of rituximab (anti-CD20). This evidence concerns the gene CD86 and rheumatoid arthritis.